Completed PHASE1 INTERVENTIONAL 6-arm NCT01059851

Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)

An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4305 in Patients With Impaired Renal Function

Sponsor: Merck Sharp & Dohme LLC

Conditions Insomnia

Interventions Suvorexant

Updated 11 times since 2017 Last updated: Oct 8, 2018 Started: May 24, 2010 Primary completion: Jul 15, 2010 Completion: Jul 15, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01059851, this PHASE1 trial focuses on Insomnia and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 11 times since 2010, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Jun 2022 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 6 earlier versions

Jan 2021 — Jun 2022 [monthly]

Completed PHASE1
Dec 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Dec 2018 [monthly]

Completed PHASE1
Aug 2017 — Jun 2018 [monthly]

Completed PHASE1
Feb 2017 — Aug 2017 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.